A Phase 1 interventional study of 1% sirolimus cream (TD201 1%) in Pachyonychia Congenita, sponsored by TransDerm, Inc.. Completed at 1 site in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2016-10-07.
Sponsored by TransDerm, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in adults with PC. Subjects may receive either placebo or treatment with at least 1 foot receiving topical sirolimus at some time. For certain phases of the study treatment assignment to the right and left foot will be randomized in a double blind fashion. Blood levels will test systemic absorption of sirolimus. Other safety and efficacy measures will be taken through the 39-week study duration. Funding Source - FDA OOPD
This is the only study on the registry with TransDerm, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must:
Exclusion Criteria:
A Subject with any of the following criteria is not eligible for inclusion in this study:
Prior and Current Treatment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.
Drug: 1% sirolimus cream (TD201 1%)
1% sirolimus cream (TD201 1%)
Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels
The primary outcome measure for this Phase 1b safety study is evaluation of system absorption through measurement of serum sirolimus trough levels. The limit of detection of the assay was 2.0 ng/mL.
Time frame: Two weeks and every 1-2 months for 24 weeks or within 2 weeks after the last dose of study drug
Weekly Assessments Recorded in the PC Quality of Life Index
Patient-reported weekly assessment in the PC Quality of Life Index
Time frame: Weekly for 39 weeks
Daily Assessments Recording in the PC Measurement Diary
Time frame: Weekly for 39 weeks
Investigator Assessment of Local Tolerability
Investigator assessment of local tolerability at the application sites on the plantar surfaces will be evaluated by the Investigator according to a 4-point scale (0, 1, 2, or 3; none to severe) with regard to: erythema, pruritis, stinging/burning, and crusting/erosion
Time frame: Prior to application of study drug and within 15-45 minutes after application of study drug at each visit for 39 weeks
Standardized Photographs
An expert in the disease who is blinded to the study treatment will read the photographs of the callus area taken at each study visit. The reader will assess changes to the calluses based on criteria such as blisters, cracks, small/large size, and red or bloody spots on the callus. Change in calluses will be reported for both the right and left foot.
Time frame: Each study visit over 39 weeks
| Milestone | Split-body 1% Sirolimus Cream (TD201 1%) |
|---|---|
| Started | 15 |
| Completed | 14 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
The primary outcome measure for this Phase 1b safety study is evaluation of system absorption through measurement of serum sirolimus trough levels. The limit of detection of the assay was 2.0 ng/mL.
| participants | Split-body 1% Sirolimus Cream (TD201 1%) |
|---|---|
| Visit 1, Baseline, <2.0 ng/mL | 15 |
| Visit 2, Week 3, <2 ng/mL | 15 |
| Visit 3, Week 7, <2 ng/mL | 15 |
| Visit 4, Week 13, <2 ng/mL | 14 |
| Visit 5, Week 17, <2 ng/mL | 14 |
| Visit 6, Week 25, <2 ng/mL | 14 |
| Visit 7, Week 37, <2 ng/mL | 14 |
Patient-reported weekly assessment in the PC Quality of Life Index
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Investigator assessment of local tolerability at the application sites on the plantar surfaces will be evaluated by the Investigator according to a 4-point scale (0, 1, 2, or 3; none to severe) with regard to: erythema, pruritis, stinging/burning, and crusting/erosion
| units on a scale | Split-body 1% Sirolimus Cream (TD201 1%) | Placebo Cream (Vehicle Control) |
|---|---|---|
| Visit 1 Pre, Erythema Score (0-3) | 0.2 ± 0.41 | 0.2 ± 0.41 |
| Visit 1 Pre, Pruritus Score (0-3) | 0.1 ± 0.26 | 0 ± 0 |
| Visit 1 Pre, Stinging/Burning (0-3) Score | 0 ± 0 | 0.1 ± 0.26 |
| Visit 1 Pre, Crusting/Erosion Score (0-3) | 0.1 ± 0.26 | 0.1 ± 0.26 |
| Visit 1 Post, Erythema Score (0-3) | 0.2 ± 0.41 | 0.2 ± 0.41 |
| Visit 1 Post, Pruritus Score (0-3) | 0 ± 0 | 0 ± 0 |
| Visit 1 Post, Stinging/Burning Score (0-3) | 0 ± 0 | 0.1 ± 0.26 |
| Visit 1 Post, Crusting/Erosion Score (0-3) | 0.1 ± 0.26 | 0.1 ± 0.26 |
| Visit 4 Pre, Erythema Score (0-3) | 0 ± 0 | 0 ± 0 |
| Visit 4 Pre, Pruritus Score (0-3) | 0.1 ± 0.28 | 0.1 ± 0.28 |
| Visit 4 Pre, Stinging/Burning Score (0-3) | 0.1 ± 0.28 | 0 ± 0 |
| Visit 4 Pre, Crusting/Erosion Score (0-3) | 0.1 ± 0.28 | 0.2 ± 0.38 |
| Visit 4 Post, Erythema Score (0-3) | 0 ± 0 | 0 ± 0 |
| Visit 4 Post, Pruritus Score (0-3) | 0 ± 0 | 0 ± 0 |
| Visit 4 Post, Stinging/Burning Score (0-3) | 0.1 ± 0.28 | 0 ± 0 |
| Visit 4 Post, Crusting/Erosion Score (0-3) | 0.1 ± 0.28 | 0.2 ± 0.38 |
| Visit 7 Pre, Erythema Score (0-3) | 0.2 ± 0.58 | 0.2 ± 0.58 |
| Visit 7 Pre, Pruritus Score (0-3) | 0.2 ± 0.58 | 0.2 ± 0.58 |
| Visit 7 Pre, Stinging/Burning Score (0-3) | 0.3 ± 0.61 | 0.3 ± 0.61 |
| Visit 7 Pre, Crusting/Erosion Score (0-3) | 0.4 ± 0.65 | 0.3 ± 0.61 |
An expert in the disease who is blinded to the study treatment will read the photographs of the callus area taken at each study visit. The reader will assess changes to the calluses based on criteria such as blisters, cracks, small/large size, and red or bloody spots on the callus. Change in calluses will be reported for both the right and left foot.
Results for this outcome have not been posted.
Collected over Duration of the study, up to 39 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Split-body 1% Sirolimus Cream (TD201 1%) | — | 0/15 (0%) | 6/15 (40%) |
| Event | Split-body 1% Sirolimus Cream (TD201 1%) |
|---|---|
| NauseaGastrointestinal disorders | 1/15 |
| PyrexiaGeneral disorders | 1/15 |
| Upper respiratory tract infectionInfections and infestations | 1/15 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/15 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 1/15 |
| Skin ulcerSkin and subcutaneous tissue disorders | 1/15 |
| UrticariaSkin and subcutaneous tissue disorders | 1/15 |
| HeadacheNervous system disorders | 1/15 |
| RhinorrheaRespiratory, thoracic and mediastinal disorders | 1/15 |
This is a split-body design. After a 2-week run in phase in which both feet were treated with placebo, feet were randomized and one foot received 1% sirolimus and the other placebo ("randomized phase") for 8 weeks. Following the randomized phase, patients applied 1% sirolimus to both feet ("open label phase") for an additional 8 weeks.
| Age, Categorical(Participants) | Split-body 1% Sirolimus Cream (TD201 1%) |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 15 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Split-body 1% Sirolimus Cream (TD201 1%) |
|---|---|
| Female | 9 |
| Male | 6 |
| Race (NIH/OMB)(Participants) | Split-body 1% Sirolimus Cream (TD201 1%) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 13 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Split-body 1% Sirolimus Cream (TD201 1%) |
|---|---|
| United States | 15 |
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Jan 2014, a primary completion of Jul 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
Pachyonychia Congenita